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Abstract
Background:
Anthracycline chemotherapies are used to treat a wide variety of malignancies. A study by Von Hoff et al
showed that 2.2% of patients previously treated with anthracycline chemotherapy were later diagnosed with
heart failure. A more recent study by Smain, et al, showed that 26% of patients receiving higher doses of
anthracycline were later diagnosed with heart failure. Statins have been shown to have properties that may
allow them to be cardioprotective. Animal research performed by Henninger et al suggests that statin therapy
is beneficial for reducing anthracycline-related cardiotoxicity in mice.It also lends evidence supporting the
theory that, among adult cancer survivors treated with anthracycline chemotherapies, statin therapy may
reduce their decline in left ventricular dysfunction, which is the aim of this systematic review.
Methods:
An exhaustive search using MEDLINE-Ovid, ClinicalKey, and Web of Science was performed using the
terms: statin, anthracycline, and heart failure. Studies were excluded if they were review articles, opinion-
based articles, animal studies, published over five years ago, or written in a language besides English. Articles
were assessed for quality using the Grading of Recommendations, Assessment, Development, and Evaluation
(GRADE) criteria.
Results:
Three studies met criteria and were used in this systematic review. A randomized controlled trial by Acar et al
found that the mean reduction in left ventricular ejection fraction (LVEF) was significantly lower in the statin
group than the control group (P < 0.0001). A retrospective observational study by Seicean et al found that
only four cases of heart failure requiring hospitalization occurred in the group receiving statin therapy, as
opposed to 23 cases in the control group (P = 0.03; HR: 0.3). Another retrospective observational study by
Chotenimitkhun et al showed a statistically significant, linear, dose-response relationship between the amount
of statin given daily and the decline in LVEF (P = 0.02).
Conclusion:
Overall, the quality of evidence supporting the use of statin therapy concurrently with anthracycline
treatment is low. However, the data from these studies is significant and warrants further investigation. Statins
are generally well tolerated medications and benefits have been shown to occur with less than one year of
therapy. The evidence would argue that the benefits of using statins concurrently and for six months following
anthracycline chemotherapy outweigh the risks unless otherwise contraindicated.
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Abstract   
 
Background:  
 
Anthracycline chemotherapies are used to treat a wide variety of malignancies. A study by Von 
Hoff et al showed that 2.2% of patients previously treated with anthracycline chemotherapy were 
later diagnosed with heart failure. A more recent study by Smain, et al, showed that 26% of 
patients receiving higher doses of anthracycline were later diagnosed with heart failure. Statins 
have been shown to have properties that may allow them to be cardioprotective. Animal research 
performed by Henninger et al suggests that statin therapy is beneficial for reducing 
anthracycline-related cardiotoxicity in mice. It also lends evidence supporting the theory that, 
among adult cancer survivors treated with anthracycline chemotherapies, statin therapy may 
reduce their decline in left ventricular dysfunction, which is the aim of this systematic review. 
 
Methods:   
 
An exhaustive search using MEDLINE-Ovid, ClinicalKey, and Web of Science was performed 
using the terms: statin, anthracycline, and heart failure. Studies were excluded if they were 
review articles, opinion-based articles, animal studies, published over five years ago, or written 
in a language besides English. Articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE) criteria. 
 
Results:   
 
Three studies met criteria and were used in this systematic review. A randomized controlled trial 
by Acar et al found that the mean reduction in left ventricular ejection fraction (LVEF) was 
significantly lower in the statin group than the control group (P < 0.0001). A retrospective 
observational study by Seicean et al found that only four cases of heart failure requiring 
hospitalization occurred in the group receiving statin therapy, as opposed to 23 cases in the 
control group (P = 0.03; HR: 0.3). Another retrospective observational study by Chotenimitkhun 
et al showed a statistically significant, linear, dose-response relationship between the amount of 
statin given daily and the decline in LVEF (P = 0.02). 
 
 
Conclusion:  
 
Overall, the quality of evidence supporting the use of statin therapy concurrently with 
anthracycline treatment is low. However, the data from these studies is significant and warrants 
further investigation. Statins are generally well tolerated medications and benefits have been 
shown to occur with less than one year of therapy. The evidence would argue that the benefits of 
using statins concurrently and for six months following anthracycline chemotherapy outweigh 
the risks unless otherwise contraindicated. 
 
Keywords:  Heart Failure, anthracycline, chemotherapy, statins 
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Among Adult Cancer Survivors Treated With Anthracycline 
Chemotherapies, Concurrent Statin Therapy May Reduce 
Their Decline in Left Ventricular Dysfunction 
BACKGROUND 
Anthracycline chemotherapies are commonly used to treat a wide variety of 
hematological malignancies, sarcomas, and breast cancers.1 This class of chemotherapeutic 
agents has many U.S. Boxed Warnings, including severe cardiotoxicity.2 It is unclear why 
anthracycline is so cardiotoxic. A number of theories such as oxidative stress and accumulation 
of free superoxide anion radicals are still being explored.3 A retrospective study by Von Hoff et 
al4 conducted in 1979 showed that 2.2% of patients previously treated with 364-390 mg/m2 of 
anthracycline chemotherapy were later diagnosed with heart failure. This study also showed a 
dose-response relationship between the amount of anthracycline given and the percent of patients 
diagnosed with heart failure.4 A more recent retrospective study by Swain et al5 conducted in 
2003 studied patients who had received higher doses of anthracycline (550 mg/m2). Among the 
participants in this study, 26% were diagnosed with heart failure.5 This side effect of 
anthracycline is associated with significant morbidity and mortality. It has been shown that 33% 
of patients who have taken anthacycline chemotherapy and experienced a decreased left 
ventricular ejection fraction (LVEF) do not return to their baseline LVEF.1 Studies have also 
shown that heart failure may have as low of a survival rate as 57% at 18 months after diagnosis.6   
Statins are beneficial for serum cholesterol reduction, but they also have antioxidative 
and anti-inflammatory properties.7 As one of the theorized mechanisms for anthracycline-
induced cardiotoxicity is oxidative stress, more research was performed to investigate statin use 
among this unique population. Animal research performed by Henninger et al8 suggests that 
statin therapy is beneficial for reducing anthracycline-related cardiotoxicity in mice. This new 
  
8 
 
research has further prompted scientists to explore the potential benefits of statin therapy. It also 
lends evidence supporting the theory that, among adult cancer survivors treated with 
anthracycline chemotherapies, statin therapy may reduce their decline in left ventricular 
dysfunction, which is the aim of this systematic review. 
METHODS 
An exhaustive literature search using MEDLINE-Ovid, ClinicalKey, and Web of Science 
was performed using the terms: statin, anthracycline, and heart failure. Studies were required to 
be published within the past five years and written in English. Studies were excluded if they 
were review articles, opinion-based articles, or animal studies. Articles were assessed for quality 
using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
criteria. 
RESULTS 
The above search resulted in 10 total articles, which were then screened for relevance. 
Three articles were found that met the inclusion criteria. One of these articles is a randomized 
controlled trial9 and the other two are retrospective observational studies10,11. See Table I. 
Acar et al 
 
This randomized control trial9 was designed to test the effect of statin therapy on patients 
receiving anthracycline chemotherapy. Its primary endpoint was impairment in LVEF utilizing 
echocardiogram measurements. This study included 40 participant, 20 of whom were randomly 
selected to be given 40 mg/day of atorvastatin during chemotherapy and for the six months 
following. The other 20 patients in the study were placed in a control group that did not receive 
statin therapy. Echocardiograms were performed on each patient both before and six months 
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after receiving anthracycline chemotherapy. Each echocardiogram was read by two separate 
cardiologists who were blinded to all patient identifiers.9 
The study excluded patients who had a history of chemotherapy, radiotherapy, heart 
failure or left ventricular dysfunction, coronary artery disease (CAD), or with moderate-to-severe 
valvular disease.  It also states that none of the patients were taking other medications that could 
alter cardiac function.9 
A two-sample t test was used to compare mean changes in LVEF between the statin 
group and the control group after chemotherapy. Within the statin group, no difference was 
found between baseline LVEF (61.3% ± 7.9%) and six month follow up LVEF (62.6% ± 9.3%). 
However, the control group experienced a significant decrease in LVEF from 62.9% ± 7.0% to 
55.0% ± 9.5% LVEF at six months. The mean reduction in LVEF was significantly lower in the 
statin group than the control group (P < 0.0001).9 
Seicean et al 
 
This retrospective observational study10 identified 628 women within the Cleveland 
Clinic Health System who had been newly diagnosed with breast cancer and received 
anthracycline chemotherapy. From this group, 67 patients were identified as being on statin 
therapy. The study matched these patients 1:2 to 134 controls by propensity score matching. The 
primary endpoint of this study was new-onset heart failure requiring hospitalization after 
initiation of anthracycline chemotherapy. They collected this data through an EMR review of 
each patient included in the study.10 
This study excluded patients who had other neoplasms, kidney or heart transplants, heart 
failure, chronic pulmonary disease, hypertrophic cardiomyopathy, valvular heart disease, aortic 
aneurism, or who were on dialysis prior to their diagnosis of breast cancer.10 
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The Wilcoxon rank sum and Pearson’s chi-square test were used when comparing the 
characteristics of patients treated with statins against those who were not treated with statins. 
Due to matching the 67 patients on statin-therapy to the controls, the two groups were of similar 
age, race, social determinants of health, smoking habits, body measurements, Charlson score, 
cancer-related treatment, and follow up time. However, patients taking statins were more likely 
to have hypertension and be taking medication with potentially cardioprotective qualities, such 
as ACE inhibitors and beta-blockers.10 
This study showed that only four cases of heart failure requiring hospitalization occurred 
in the group receiving statin therapy, as opposed to 23 cases in the control group. The 
cardioprotective effect of statins was significant when using a nested Cox proportional hazards 
model (HR: 0.3; 95% CI: 0.1-0.9; p = 0.03).10 
Chotenimitkhun et al 
 
This retrospective observational study11 identified 51 participants from the 
Comprehensive Cancer Center at Wake Forest Health Sciences with breast cancer, leukemia, or 
lymphoma who had been treated with anthracycline chemotherapy. Among this group, 14 
patients were receiving statin therapy and 37 patients were not. This study also subdivided the 
statin group into patients taking high-dose statins (40-80 mg/day) and those taking low-dose 
statins (10-20 mg/day). The primary endpoint of this study was impairment in LVEF. This was 
measured through cardiovascular magnetic resonance imaging (CMRI) measurements by blinded 
personnel taken before and six months after treatment with anthracycline chemotherapy.11 
The study excluded patients who were receiving radiation therapy during their course of 
anthracycline chemotherapy. A two-sample t test was used to compare the statin group to the 
control group. This study showed that those receiving high-dose statin (40-80mg) actually had an 
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increase in LVEF. However, those receiving low-dose statin therapy (10-20mg) had a 3.4% ± 
4% decrease in LVEF and patients not receiving stating therapy had a 9.2% ± 3% decrease in 
LVEF (P = 0.02). This study also found a statistically significant, linear, dose-response 
relationship between the amount of statin taken and the decline in LVEF (P = 0.006).11 
DISCUSSION 
Acar et al 
 
The article by Acar et al9 is a randomized controlled trial that has both strengths and 
limitations. Among the studies included in this review, this study is the only one where patients 
were randomly allocated to the statin and the control group. Also, within the statin group, the 
amount and duration of statin therapy was consistent. The statin and control groups were similar 
in regard to age, sex, cancer diagnosis, and chemotherapeutic treatment. Also, unlike either of 
the observational studies, none of the patients on statin therapy were taking other medications 
that could alter cardiac function and skew the study’s results.9 
This study also had limitations. It had a very small sample size, with only 20 patients 
allocated to each group. It also had a very short follow up of six months following each patient’s 
anthracycline chemotherapy treatment. Another limitation is that patients in the control group 
were not receiving a placebo. However, this had minimal effect on the results of the study since 
the primary outcome was LVEF read from echocardiograms; a minimally subjective endpoint.9 
Overall, even with some limitations, the results of this study are significant. No 
significant difference in mean LVEF was appreciated in the statin group (P=0.144). The control 
group, however, showed a significant decline in LVEF (P<0.0001). Although this study was 
small, it did not lose any participants during the follow-up process, which adds to its credibility 
and decreases its risk of bias. Also, the short duration of the study would be more likely to under-
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estimate the decline in patient’s LVEF because anthacycline cardiotoxicity most often occurs 
within one year of the last medication dose given.4 There is a chance that the study missed the 
more subtle decline in LVEF experienced by patients with a more delayed or more mild response 
to their anthracycline treatment. This article’s quality of evidence is technically categorized as 
moderate (see Table I). Due to the quality and significance of the study’s findings, clinicians 
should weigh this evidence carefully during their decision making process.9  
Seicean et al 
 
The retrospective observational study by Seicean et al10 was strengthened by the larger 
group of patients involved (201 total). The researchers also matched patients on statin therapy to 
those in the control group 1:2. Therefore, the groups were similar in regards to prognostic 
factors. The primary outcome chosen in this study was also more specific and clinically 
significant than the primary outcomes in the other two studies. Secean et al10 chose to study heart 
failure requiring hospitalization as opposed to studying LVEF, which would show the more 
subtle declines in cardiac function.10 
The main limitation of this study is that patients in the statin group were more likely to be 
receiving ACE inhibitors and beta-blockers. These are medications which have also been 
hypothesized to be cardioprotective.13 The researchers were unsure if they were able to 
adequately adjust for this factor in their research. For this reason, the article’s quality of evidence 
is categorized as “very low”. (See Table I)10 
Even with a reduction in evidence quality, the results of this study were significant. It 
showed a hazard ratio of 0.3 and a P value of 0.03, which means that there was a 70% reduction 
in heart failure hospitalization rate among patients on statin therapy. Also, similar to the study by 
Acar et al9, this study may under-estimate the cardioprotective effects of statin therapy because it 
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did not count the number of patients diagnosed with heart failure in outpatient settings or 
declines in LVEF found on echocardiogram.10 
Chotenimitkhun et al 
 
The retrospective observational study by Chotenimitkhun et al11 is categorized as very 
low quality of evidence (see Table I). It is limited by a very small number of participants, 51 
total and only 14 receiving statin therapy. Also, the group receiving statin therapy was not 
matched to the control group. Therefore, the patients receiving statin therapy were older and 
more likely to have diabetes, hypertension, and hyperlipidemia. Similarly to the study by Seicean 
et al,10 the patients taking statins were also more likely to be taking other potentially 
cardioprotective medications.11 
The main strength of this study is that the endpoint of LVEF is objective. Also, the 
cardiologists reading the echocardiograms were blinded to all patient identifiers.11 
Arguably, the most interesting part of this study is that a statistically significant, linear 
dose-response was found between the amount of statin given and the cardioprotective effects 
seen on echocardiogram (P = 0.006). The study also found a significant decline in LVEF among 
the patients not receiving statins (P = 0.02). Although the quality of evidence is very low, this 
study would suggest that if patients are going to be given statins during anthracycline 
chemotherapy treatment, they should be given a high dose (40-80 mg/day) rather than lower 
doses, which did not show as much cardiac benefit.11 
CONCLUSION 
Overall, the quality of evidence supporting the use of statin therapy concurrently with 
anthracycline is low. This area of research is very young and the studies that have been done are 
either restrospective observational studies or very small, short duration randomized controlled 
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trials. However, the data from these studies are significant and warrant further investigation with 
larger, longer duration, randomized controlled trials. 
Heart failure is a disease with a significant mortality rate and is a major problem for adult 
cancer survivors who have received anthracycline chemotherapy. Statins are generally well 
tolerated medications with few significant side effects. Also, there is evidence that statins are 
beneficial with less than one year of therapy. In summary, the current evidence suggests that the 
benefits of using statins concurrently and for six months after anthracycline chemotherapy 
outweigh the risks unless otherwise contraindicated.  
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Table I: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Acar et al RCT Not Serious Not Serious Not Serious Seriousa Not Likely None Moderate 
Seicean et 
al 
Retrospective 
Observational 
Seriousb Not Serious Not Serious Not Serious Not Likely Significant 
Effectc 
Very Low 
Chotenimit
-khun et al. 
Retrospective 
Observational 
Seriousd Not Serious Not Serious Seriouse Not Likely Dose- 
Responsef 
Very Low 
a The study had a very small sample size, with only 40 participants total. 
b The study did not adjust for patients in the statin group also taking other potentially cardioprotective medications. 
c  This study had a HR of 0.3. 
d The study had poor exclusion criteria and they did not match the demographics of the control group to that of the therapy group. 
e The study had a very small sample size, with only 51 participants total. 
f This study showed a dose-response with patients receiving high-dose (40-80mg) statins having an improvement in LVEF rather than  
lessened decline, as seen in patients receiving low-dose (10-20mg) statins. 
